Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 1—January 2007

Research

Model for Assessing Human Papillomavirus Vaccination Strategies

Elamin H. Elbasha*Comments to Author , Erik J. Dasbach*, and Ralph P. Insinga*
Author affiliations: *Merck Research Laboratories, North Wales, Pennsylvania, USA;

Main Article

Figure 2

Human papillomavirus (HPV) prevalence by sex and age group, as predicted by the model and reported in selected studies from North America. HPV high risk includes types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82.

Figure 2. Human papillomavirus (HPV) prevalence by sex and age group, as predicted by the model and reported in selected studies from North America. HPV high risk includes types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82.

Main Article

TOP